The present invention relates to transgenic animals comprising a mutation or deletion to the ANF-RGC protein, particularly to its ARM and/or its ATS-ST region. Such animals may be used to study the effects on pathways associated with ANF-RGC activation, including, but not limited to, hypertension. Such animals may also be used in drug screen assays, to establish toxicity profiles, or other similar methods discussed herein known in the art.
